Results 91 to 100 of about 15,940 (198)

Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review

Vaccines
Checkpoint inhibitor therapy revolutionized the treatment of patients with melanoma. However, in patients where melanoma exhibits resistance to checkpoint inhibitor therapy, the treatment options are limited.
Ayushi Garg, Rohit Rao, Felicia Tejawinata, Gazi Amena Noor Shamita, McKay S. Herpel, Akihiro Yoshida, Gordon Goolamier, Jessica Sidiropoulos, Iris Y. Sheng, Salim-Tamuz Abboud, Luke D. Rothermel, Nami Azar, Ankit Mangla   +12 more
doaj   +1 more source

Langat Virus Biology and Infection

Reviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT Flaviviruses pose a major threat to global health and can cause severe disease in animals and humans. Among them, tick‐borne encephalitis virus (TBEV) and related members of the tick‐borne encephalitis (TBE) serocomplex are transmitted primarily by ticks and can lead to neurological disease, including encephalitis and death. Despite many years
Zinaida Klestova, Daniel Sauter, Michael Schindler, Thomas Iftner   +3 more
wiley   +1 more source

Mitoxyperilysis: A Novel Cell Death Pathway With Transformative Implications for Organ Pathophysiology and Therapeutic Innovation

Organ Medicine, EarlyView.
Wenhao Shen, Junmei Li, Weifeng Hu
wiley   +1 more source

Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy

WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.
Myeloid‐derived suppressor cells (MDSCs) are key contributors to cancer immunotherapy failure and major targets in new therapeutic strategies. We highlight therapeutic approaches to counteract their immunosuppressive functions and discuss recent efforts to optimize drug delivery for controlling MDSCs, focusing on resiquimod as a representative drug ...
Yanying He, Yoon Yeo
wiley   +1 more source

The Application of PD‐1 Inhibitors in Immunotherapy for Glioblastoma

The FASEB Journal, Volume 40, Issue 4, 28 February 2026.
The molecular mechanism of PD‐1. When PD‐1 binds to PD‐L1, the ITIM and ITSM domains within PD‐1 are phosphorylated and subsequently recruit SHP‐2. This then dephosphorylates downstream molecules of the TCR, such as PI3K/AKT and ZAP70, reduces the secretion of IFN‐γ, and inhibits the presentation of antigens to T cells via MHC molecules through the ...
Ming‐zhen Dong, Ming Cui, Lin‐zhuo Qu, Hui‐ying Che, Hong‐jian Guan   +4 more
wiley   +1 more source

A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma

Cancer, Volume 132, Issue 4, 15 February 2026.
Abstract Background Pembrolizumab is approved for advanced cutaneous melanoma (aCM). Cabozantinib, an oral multi‐tyrosine kinase inhibitor, has demonstrated antitumor activity as monotherapy or in combination with anti‐PD‐1 therapy in malignancies. The objective of this study was to determine the safety and efficacy of cabozantinib and pembrolizumab ...
Yousef Zakharia, Donghyun Kim, Michele Freesmeier, Melanie Frees, Sarah Mott, Varun Monga, Douglas Laux, Asad Javed, John Rieth, John Smestad, Mohammed Milhem   +10 more
wiley   +1 more source

Oncolytics, Cancer-Fighting Viruses from Past to Future: A Literature Review [PDF]

پیاورد سلامت
Background and Aim: Oncolytic viruses, as novel and advanced tools in the field of treating various types of cancer, have played a very important role in medical developments.
Seyedeh Nasim Mirbahari, Sina Salari, Shabnam Shahrokh, Mohammadreza Zali, Mehdi Totonchi   +4 more
doaj  

The Potency of Mesenchymal Stem Cells as Viral Oncolytic Carriers

Clinical and Research Journal in Internal Medicine
Oncolytic viruses (OVs) represent a category of viruses that selectively replicate within tumor cells, destroying cancer cells through a dual mechanism involving viral oncolysis and the stimulation of the host's anti-tumor immune response.
Muhammad Farid Rakhman
doaj   +1 more source

Oncolytic viruses: advanced strategies in cancer therapy. [PDF]

Signal Transduct Target Ther
Xiao D, Zhang H, Liu Y, Li Y, Li G, Ning Y.   +5 more
europepmc   +1 more source

Oncolytic viruses: Revolutionising the fight against tumours. [PDF]

Clin Transl Med
Zhao Z, Shen Y, Liang T.
europepmc   +1 more source